Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

V 0162

Drug Profile

V 0162

Alternative Names: V0162; VO-162

Latest Information Update: 25 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pierre Fabre
  • Developer Pierre Fabre; SGS
  • Class Phenothiazines; Small molecules
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M2 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma
  • Suspended Overactive bladder
  • No development reported Chronic obstructive pulmonary disease
  • Discontinued Urinary incontinence

Most Recent Events

  • 25 Aug 2015 Discontinued - Phase-II for Urinary incontinence in Europe (unspecified route)
  • 25 Aug 2015 No recent reports on development identified - Phase-I/II for Chronic obstructive pulmonary disease in Belgium and France (Inhalation)
  • 30 Sep 2013 Phase-II clinical trials in Asthma in Germany (Unspecified route) (NCT01951222)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top